Clinical and laboratory values stratified by type of thrombotic event in patients with SCD
| . | n . | No thrombosis . | n . | CVA . | n . | Venous thrombosis . |
|---|---|---|---|---|---|---|
| Age at first encounter, y | 985 | 23 (15-35) | 50 | 26 (19-40) | 172 | 27 (21-40)** |
| Male/female, % | 985 | 45/55 | 50 | 40/60 | 172 | 35/65* |
| African American, n (%) | 985 | 923 (94) | 50 | 49 (98) | 172 | 165 (96) |
| Sickle cell genotype, n (%) | 985 | 50 | 172 | |||
| HbSS/SB0-thalassemia | 657 (66.7) | 44 (88.0)* | 141 (82.0)** | |||
| HbSC or HbSB+-thalassemia or other | 328 (33.3) | 6 (12.0) | 31 (18.0) | |||
| Hydroxyurea use, n (%) | 985 | 496 (50) | 50 | 34 (68) | 172 | 141 (82)** |
| Tobacco use, n (%) | 985 | 266 (27%) | 50 | 15 (30%) | 172 | 75 (44%)** |
| Body mass index, kg/m2 | 985 | 22 (18-26) | 50 | 23 (20-26) | 172 | 23 (20-28)** |
| Systolic blood pressure, mm Hg | 985 | 115 (104-127) | 50 | 122 (110-130) | 172 | 122 (110-134)** |
| White blood cell count, ×103/μL | 985 | 9.7 (7.4-12.2) | 50 | 9.1 (6.6-12.1) | 172 | 10.2 (7.7-12.9)* |
| Platelet count, ×103/μL | 985 | 406 (287-525) | 50 | 392 (335-569) | 172 | 404 (311-529) |
| Hb, g/dL | 985 | 9.6 (8.3-11.1) | 50 | 8.8 (7.9-9.6)* | 172 | 9.0 (8.3-10.3)* |
| Hb F, % | 985 | 4.9 (2.1-11.2) | 50 | 2.5 (1.1-7.8)* | 172 | 5.2 (2.3-9.9) |
| Reticulocyte count, ×103/μL | 985 | 249 (158-384) | 50 | 283 (249-488)* | 172 | 291 (193-415)* |
| Lactate dehydrogenase, U/L | 985 | 289 (222-408) | 50 | 414 (296-481)** | 172 | 323 (234-440) |
| AST, U/L | 985 | 35 (25-47) | 50 | 44 (30-58)* | 172 | 37 (28-53) |
| Serum creatinine, mg/dL | 985 | 0.7 (0.5-0.8) | 50 | 0.7 (0.6-1.0)* | 172 | 0.7 (0.6-0.9)** |
| eGFR, mL/min/1.73 m2 | 985 | 146 (119-171) | 50 | 138 (95-154)* | 172 | 136 (102-155)** |
| Hospitalizations, no. per year | 985 | 1 (0-3) | 50 | 1 (1-4) | 172 | 4 (1-9)** |
| Pregnancies, n (%) of patients | 545 | 30 | 112 | |||
| Before the first thrombotic event | 105 (19) | 1 (4)* | 23 (21) | |||
| During the entire time period | 3 (10) | 31 (28)* | ||||
| Orthopedic procedures, n (%) of patients | 985 | 50 | 172 | |||
| Before the first thrombotic event | 29 (3) | 3 (6) | 8 (5) | |||
| During the entire time period | 5 (10)* | 19 (11)** | ||||
| Central venous catheters, n (%) of patients | 985 | 50 | 172 | |||
| Before the first thrombotic event | 244 (25) | 16 (32) | 89 (52)** | |||
| During the entire time period | 36 (72)** | 125 (72)** |
| . | n . | No thrombosis . | n . | CVA . | n . | Venous thrombosis . |
|---|---|---|---|---|---|---|
| Age at first encounter, y | 985 | 23 (15-35) | 50 | 26 (19-40) | 172 | 27 (21-40)** |
| Male/female, % | 985 | 45/55 | 50 | 40/60 | 172 | 35/65* |
| African American, n (%) | 985 | 923 (94) | 50 | 49 (98) | 172 | 165 (96) |
| Sickle cell genotype, n (%) | 985 | 50 | 172 | |||
| HbSS/SB0-thalassemia | 657 (66.7) | 44 (88.0)* | 141 (82.0)** | |||
| HbSC or HbSB+-thalassemia or other | 328 (33.3) | 6 (12.0) | 31 (18.0) | |||
| Hydroxyurea use, n (%) | 985 | 496 (50) | 50 | 34 (68) | 172 | 141 (82)** |
| Tobacco use, n (%) | 985 | 266 (27%) | 50 | 15 (30%) | 172 | 75 (44%)** |
| Body mass index, kg/m2 | 985 | 22 (18-26) | 50 | 23 (20-26) | 172 | 23 (20-28)** |
| Systolic blood pressure, mm Hg | 985 | 115 (104-127) | 50 | 122 (110-130) | 172 | 122 (110-134)** |
| White blood cell count, ×103/μL | 985 | 9.7 (7.4-12.2) | 50 | 9.1 (6.6-12.1) | 172 | 10.2 (7.7-12.9)* |
| Platelet count, ×103/μL | 985 | 406 (287-525) | 50 | 392 (335-569) | 172 | 404 (311-529) |
| Hb, g/dL | 985 | 9.6 (8.3-11.1) | 50 | 8.8 (7.9-9.6)* | 172 | 9.0 (8.3-10.3)* |
| Hb F, % | 985 | 4.9 (2.1-11.2) | 50 | 2.5 (1.1-7.8)* | 172 | 5.2 (2.3-9.9) |
| Reticulocyte count, ×103/μL | 985 | 249 (158-384) | 50 | 283 (249-488)* | 172 | 291 (193-415)* |
| Lactate dehydrogenase, U/L | 985 | 289 (222-408) | 50 | 414 (296-481)** | 172 | 323 (234-440) |
| AST, U/L | 985 | 35 (25-47) | 50 | 44 (30-58)* | 172 | 37 (28-53) |
| Serum creatinine, mg/dL | 985 | 0.7 (0.5-0.8) | 50 | 0.7 (0.6-1.0)* | 172 | 0.7 (0.6-0.9)** |
| eGFR, mL/min/1.73 m2 | 985 | 146 (119-171) | 50 | 138 (95-154)* | 172 | 136 (102-155)** |
| Hospitalizations, no. per year | 985 | 1 (0-3) | 50 | 1 (1-4) | 172 | 4 (1-9)** |
| Pregnancies, n (%) of patients | 545 | 30 | 112 | |||
| Before the first thrombotic event | 105 (19) | 1 (4)* | 23 (21) | |||
| During the entire time period | 3 (10) | 31 (28)* | ||||
| Orthopedic procedures, n (%) of patients | 985 | 50 | 172 | |||
| Before the first thrombotic event | 29 (3) | 3 (6) | 8 (5) | |||
| During the entire time period | 5 (10)* | 19 (11)** | ||||
| Central venous catheters, n (%) of patients | 985 | 50 | 172 | |||
| Before the first thrombotic event | 244 (25) | 16 (32) | 89 (52)** | |||
| During the entire time period | 36 (72)** | 125 (72)** |
Values are median (IQR) unless otherwise noted.
*P < .05; **P < .002 (statistically significant after Bonferroni correction).